Litman Gregory Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Litman Gregory Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$614	Buy	+150	New	+$743	﹤0.01%	337

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Litman Gregory Wealth Management's RXRX Position: Q4 2025 in Review

Litman Gregory Wealth Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2025: 150 shares worth $614. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings.

334 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Litman Gregory Wealth Management held 150 shares of Recursion Pharmaceuticals worth $614 as of Q4 2025.
Recursion Pharmaceuticals was a new Litman Gregory Wealth Management position in Q4 2025.
Recursion Pharmaceuticals made up ﹤0.01% of Litman Gregory Wealth Management's portfolio in Q4 2025, its #337 holding.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Litman Gregory Wealth Management's 13F filing for Q4 2025, filed 12 Feb 2026.